{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:40:02Z","timestamp":1776177602444,"version":"3.50.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS) is a debilitating multi-systemic chronic condition of unknown aetiology classified as an immune dysfunction syndrome and neurological disorder. The discovery of the widely expressed Transient Receptor Potential Melastatin 3 (TRPM3) as a nociceptor channel substantially targeted by certain opioid receptors, and its implication in calcium (Ca\n                    <jats:sup>2+<\/jats:sup>\n                    )-dependent Natural Killer (NK) cell immune functions has raised the possibility that TRPM3 may be pharmacologically targeted to treat characteristic symptoms of ME\/CFS. Naltrexone hydrochloride (NTX) acts as an antagonist to the mu (\u03bc)-opioid receptor thus negating its inhibitory function on TRPM3. Based on the benefits reported by patients on their symptoms, low dose NTX (LDN, 3.0\u20135.0\u2005mg\/day) treatment seems to offer some potential benefit suggesting that its effect may be targeted towards the pathomechanism of ME\/CFS. As there is no literature confirming the efficacy of LDN for ME\/CFS patients\n                    <jats:italic>in vitro<\/jats:italic>\n                    , this study investigates the potential therapeutic effect of LDN in ME\/CFS patients. TRPM3 ion channel activity was measured after modulation with Pregnenolone sulfate (PregS) and ononetin in NK cells on 9 ME\/CFS patients taking LDN and 9 age- and sex-matched healthy controls using whole-cell patch-clamp technique. We report that ME\/CFS patients taking LDN have restored TRPM3-like ionic currents in NK cells. Small ionic currents with a typical TRPM3-like outward rectification were measured after application of PregS, a TRPM3-agonist, in NK cells from patients taking LDN. Additionally, PregS-evoked ionic currents through TRPM3 were significantly modulated by ononetin, a TRPM3-antagonist, in NK cells from ME\/CFS patients taking LDN. These data support the hypothesis that LDN may have potential as a treatment for ME\/CFS by characterising the underlying regulatory mechanisms of LDN treatment involving TRPM3 and opioid receptors in NK cells. Finally, this study may serve for the repurpose of marketed drugs, as well as support the approval of prospective randomized clinical studies on the role and dose of NTX in treating ME\/CFS patients.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.687806","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T02:23:50Z","timestamp":1626143030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Helene","family":"Cabanas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Muraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Eaton-Fitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald Ross","family":"Staines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonya","family":"Marshall-Gradisnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-12-199412150-00009","article-title":"The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study. International Chronic Fatigue Syndrome Study Group","volume":"121","author":"Fukuda","year":"1994","journal-title":"Ann Intern Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02428.x","article-title":"Myalgic Encephalomyelitis: International Consensus Criteria","volume":"270","author":"Carruthers","year":"2011","journal-title":"J Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/1742395316644770","article-title":"Housebound Versus Nonhousebound Patients With Myalgic Encephalomyelitis and Chronic Fatigue Syndrome","volume":"12","author":"Pendergrast","year":"2016","journal-title":"Chronic Illn"},{"key":"B4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13317-013-0051-x","article-title":"Natural Killer Cells in Patients With Severe Chronic Fatigue Syndrome","volume":"4","author":"Brenu","year":"2013","journal-title":"Auto Immun Highlights"},{"key":"B5","article-title":"Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: A Clinical Case Definition and Guidelines for Medical Practitioners\u202f: An Overview of the Canadian Consensus Document","author":"Carruthers","year":"2005","journal-title":"Calgary"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1300\/J092v11n01_02","article-title":"Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome","volume":"11","author":"Carruthers","year":"2003","journal-title":"J Chronic Fatigue Syndrome"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12967-020-02269-0","article-title":"Systematic Review and Meta-Analysis of the Prevalence of Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis (CFS\/ME)","volume":"18","author":"Lim","year":"2020","journal-title":"J Trans Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TACG.S99405","article-title":"Natural Killer Cells and Single Nucleotide Polymorphisms of Specific Ion Channels and Receptor Genes in Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome","volume":"9","author":"Marshall-Gradisnik","year":"2016","journal-title":"Appl Clin Genet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40659-016-0087-2","article-title":"Novel Identification and Characterisation of Transient Receptor Potential Melastatin 3 Ion Channels on Natural Killer Cells and B Lymphocytes: Effects on Cell Signalling in Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis Patients","volume":"49","author":"Nguyen","year":"2016","journal-title":"Biol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12882","article-title":"Impaired Calcium Mobilization in Natural Killer Cells From Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis Patients Is Associated With Transient Receptor Potential Melastatin 3 Ion Channels","volume":"187","author":"Nguyen","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s10020-018-0046-1","article-title":"Loss of Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis Patients","volume":"24","author":"Cabanas","year":"2018","journal-title":"Mol Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-019-0083-4","article-title":"Validation of Impaired Transient Receptor Potential Melastatin 3 Ion Channel Activity in Natural Killer Cells From Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis Patients","volume":"25","author":"Cabanas","year":"2019","journal-title":"Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02545","article-title":"Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome Patients","volume":"10","author":"Cabanas","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.02.051","article-title":"TRPM3 Is a Nociceptor Channel Involved in the Detection of Noxious Heat","volume":"70","author":"Vriens","year":"2011","journal-title":"Neuron"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.26138","article-title":"G Protein \u03b2\u03b3 Subunits Inhibit TRPM3 Ion Channels in Sensory Neurons","volume":"6","author":"Quallo","year":"2017","journal-title":"Elife"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.26280","article-title":"Anti-Nociceptive Action of Peripheral Mu-Opioid Receptors by G-Beta-Gamma Protein-Mediated Inhibition of TRPM3 Channels","volume":"6","author":"Dembla","year":"2017","journal-title":"Elife"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.26147","article-title":"Inhibition of Transient Receptor Potential Melastatin 3 Ion Channels by G-Protein \u03b2\u03b3 Subunits","volume":"6","author":"Badheka","year":"2017","journal-title":"Elife"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0882-19.2019","article-title":"Promiscuous G-Protein-Coupled Receptor Inhibition of Transient Receptor Potential Melastatin 3 Ion Channels by G\u03b2\u03b3 Subunits","volume":"39","author":"Alkhatib","year":"2019","journal-title":"J Neurosci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062613-093100","article-title":"Opioid Receptors","volume":"67","author":"Stein","year":"2016","journal-title":"Annu Rev Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00300","article-title":"Opioid Receptors in Immune and Glial Cells-Implications for Pain Control","volume":"11","author":"Machelska","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2016.04.018","article-title":"Leukocyte Opioid Receptors Mediate Analgesia via Ca(2+)-Regulated Release of Opioid Peptides","volume":"57","author":"Celik","year":"2016","journal-title":"Brain Behav Immun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00726-011-1163-0","article-title":"Role of the Mu-Opioid Receptor in Opioid Modulation of Immune Function","volume":"45","author":"Ninkovi\u0107","year":"2013","journal-title":"Amino Acids"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00088","article-title":"The Neuroinflammatory Etiopathology of Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS)","volume":"8","author":"Glassford","year":"2017","journal-title":"Front Physiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12916-014-0259-2","article-title":"Central Pathways Causing Fatigue in Neuro-Inflammatory and Autoimmune Illnesses","volume":"13","author":"Morris","year":"2015","journal-title":"BMC Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00809","article-title":"Naltrexone Inhibits IL-6 and TNF\u03b1 Production in Human Immune Cell Subsets Following Stimulation With Ligands for Intracellular Toll-Like Receptors","volume":"8","author":"Cant","year":"2017","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301440","article-title":"Differences in Delta- and Mu-Opioid Receptor Blockade Measured by Positron Emission Tomography in Naltrexone-Treated Recently Abstinent Alcohol-Dependent Subjects","volume":"33","author":"Weerts","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/21641846.2019.1692770","article-title":"Low-Dose Naltrexone in the Treatment of Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS)","volume":"7","author":"Polo","year":"2019","journal-title":"Fatigue: Biomed Health Behav"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/1535370217724791","article-title":"Featured Article: Serum [Met5]-Enkephalin Levels Are Reduced in Multiple Sclerosis and Restored by Low-Dose Naltrexone","volume":"242","author":"Ludwig","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-013-9451-y","article-title":"Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN)","volume":"8","author":"Chopra","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2517-2","article-title":"The Use of Low-Dose Naltrexone (LDN) as a Novel Anti-Inflammatory Treatment for Chronic Pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines5020016","article-title":"Reduced Pro-Inflammatory Cytokines After Eight Weeks of Low-Dose Naltrexone for Fibromyalgia","volume":"5","author":"Parkitny","year":"2017","journal-title":"Biomedicines"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 Health Survey Update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine"},{"key":"B33","unstructured":"WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-81","article-title":"Immunological Abnormalities as Potential Biomarkers in Chronic Fatigue Syndrome\/Myalgic Encephalomyelitis","volume":"9","author":"Brenu","year":"2011","journal-title":"J Trans Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.340","article-title":"Highly Purified Selective Isolation of Eosinophils From Human Peripheral Blood by Negative Immunomagnetic Selection","volume":"1","author":"Munoz","year":"2006","journal-title":"Nat Protoc"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e8343","DOI":"10.1371\/journal.pone.0008343","article-title":"Normative Data for the 12 Item WHO Disability Assessment Schedule 2.0","volume":"4","author":"Andrews","year":"2009","journal-title":"PloS One"},{"key":"B37","unstructured":"Australian Institute of Health and WelfareSF-36 interim norms for Australian data, Summary"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e232502","DOI":"10.1136\/bcr-2019-232502","article-title":"Low-Dose Naltrexone as a Treatment for Chronic Fatigue Syndrome","volume":"13","author":"Bolton","year":"2020","journal-title":"BMJ Case Rep CP"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12076","article-title":"Citrus Fruit and Fabacea Secondary Metabolites Potently and Selectively Block TRPM3","volume":"168","author":"Straub","year":"2013","journal-title":"Br J Pharmacol"},{"key":"B40","article-title":"The Use of Naltrexone in Low Doses Beyond the Approved Indication","volume":"8","author":"Ringerike","year":"2015","journal-title":"NIPH Syst Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0114","article-title":"Treatment of Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop","volume":"162","author":"Smith","year":"2015","journal-title":"Ann Intern Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22006","article-title":"Pilot Trial of Low-Dose Naltrexone and Quality of Life in Multiple Sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann Neurol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005180","article-title":"Effects of Naltrexone on Pain Sensitivity and Mood in Fibromyalgia: No Evidence for Endogenous Opioid Pathophysiology","volume":"4","author":"Younger","year":"2009","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/medsci6040082","article-title":"Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization","volume":"6","author":"Toljan","year":"2018","journal-title":"Med Sci (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-54215-2_17","article-title":"TRPM3","volume":"222","author":"Oberwinkler","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s00429-017-1380-8","article-title":"Store-Operated Calcium Entry Is Essential for Glial Calcium Signalling in CNS White Matter","volume":"222","author":"Papanikolaou","year":"2017","journal-title":"Brain Struct Funct"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-010-0838-9","article-title":"TRPM3 Channels Provide a Regulated Influx Pathway for Zinc in Pancreatic Beta Cells","volume":"460","author":"Wagner","year":"2010","journal-title":"Pflugers Arch"},{"key":"B48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/BST20110766","article-title":"Calcium Signalling Remodelling and Disease","volume":"40","author":"Berridge","year":"2012","journal-title":"Biochem Soc Trans"},{"key":"B49","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nri2152","article-title":"Calcium Signalling in Lymphocyte Activation and Disease","volume":"7","author":"Feske","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.139.6.1772","article-title":"Induction of Calcium Flux and Enhancement of Cytolytic Activity in Natural Killer Cells by Cross-Linking of the Sheep Erythrocyte Binding Protein (CD2) and the Fc-Receptor (CD16)","volume":"139","author":"Anasetti","year":"1987","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev.iy.03.040185.000335","article-title":"Mechanism of Lymphocyte-Mediated Cytotoxicity","volume":"3","author":"Henkart","year":"1985","journal-title":"Annu Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1289\/ehp.99107s125","article-title":"Calcium Signaling and Cytotoxicity","volume":"107","author":"Kass","year":"1999","journal-title":"Environ Health Perspect"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2012.11.016","article-title":"Calcium, Cancer and Killing: The Role of Calcium in Killing Cancer Cells by Cytotoxic T Lymphocytes and Natural Killer Cells","volume":"1833","author":"Schwarz","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B54","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13643-019-1202-6","article-title":"A Systematic Review of Natural Killer Cells Profile and Cytotoxic Function in Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome","volume":"8","author":"Eaton-Fitch","year":"2019","journal-title":"Syst Rev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.11138\/ccmbm\/2014.11.3.165","article-title":"Pain Pharmacology: Focus on Opioids","volume":"11","author":"Fornasari","year":"2014","journal-title":"Clin cases Miner Bone Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-006-9026-2","article-title":"Opioid Receptors and Signaling on Cells From the Immune System","volume":"1","author":"Bidlack","year":"2006","journal-title":"J Neuroimmune Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13750","article-title":"Opioids and the Immune System \u2013 Friend or Foe","volume":"175","author":"Plein","year":"2018","journal-title":"Br J Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2020\/e1554","article-title":"Opioid-Induced Immunosuppression and Carcinogenesis Promotion Theories Create the Newest Trend in Acute and Chronic Pain Pharmacotherapy","volume":"75","author":"Kosciuczuk","year":"2020","journal-title":"Clinics"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bbi.2005.02.002","article-title":"Multiple Opioid Receptors on Immune Cells Modulate Intracellular Signaling","volume":"20","author":"Sharp","year":"2006","journal-title":"Brain Behavior Immun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(03)00003-6","article-title":"Opioid G Protein-Coupled Receptors: Signals at the Crossroads of Inflammation","volume":"24","author":"Rogers","year":"2003","journal-title":"Trends Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2234","article-title":"Interactions Between the Immune and Nervous Systems in Pain","volume":"16","author":"Ren","year":"2010","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/jir.2009.0008","article-title":"Opioid-Like Activity of Naltrexone on Natural Killer Cell Cytolytic Activity and Cytokine Production in Splenocytes: Effects of Alcohol","volume":"30","author":"Boyadjieva","year":"2010","journal-title":"J Interferon Cytokine Res"},{"key":"B64","article-title":"Decreased Immunoreactive Beta-Endorphin in Mononuclear Leucocytes From Patients With Chronic Fatigue Syndrome","volume":"16","author":"Conti","year":"1998","journal-title":"Clin Exp Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.687806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T18:07:59Z","timestamp":1672769279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.687806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2021.687806"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.687806","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740503310.793587268","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"article-number":"687806"}}